{
    "clinical_study": {
        "@rank": "153192", 
        "arm_group": {
            "arm_group_label": "Study Group", 
            "description": "A random sample of subjects constituting adolescents and young adults (\u226510 - \u226425 years of age) that participated in the ENSANUT 2012 in Mexico."
        }, 
        "biospec_descr": {
            "textblock": "Stored serum samples of the selected subjects obtained from the ENSANUT 2012"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study will assess the seroprevalence of hepatitis A virus (HAV), hepatitis B virus\n      (HBV) and Bordetella pertussis (B. pertussis) in adolescents and young adults in Mexico."
        }, 
        "brief_title": "Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis A", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Whooping Cough"
            ]
        }, 
        "detailed_description": {
            "textblock": "A random sample of subjects constituting adolescents and young adults (\u226510 - \u226425 years of\n      age) will be selected from the total population that participated in the Encuesta Nacional\n      de Salud y Nutrici\u00f3n (ENSANUT) 2012 in Mexico.\n\n      Data (through structured questionnaires and interviews) and stored serum samples of the\n      selected subjects obtained from the ENSANUT 2012 will be used in this study. A subset\n      database will be designed by the National Institute of Public Health (NIPH) for the purpose\n      of this study. Extracted data and laboratory results of the selected subjects will be\n      captured in this database."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent for the ENSANUT 2012 was obtained according to local\n             regulations from the subject/ from the parent(s)/ legally acceptable representative\n             (LAR) of the subject.\n\n          -  A male or female between and including 10 and 25 years of age, who previously\n             participated in the ENSANUT 2012 in Mexico.\n\n        Exclusion Criteria:\n\n          -  Information required for the study is not available or incomplete.\n\n          -  Inadequate or insufficient serum sample to perform the laboratory tests for this\n             study.\n\n          -  Serum sample is wrongly identified."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "25 Years", 
            "minimum_age": "10 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects constituting adolescents and young adults (\u226510 - \u226425 years of age) from the total\n        population that participated in the ENSANUT 2012 in Mexico."
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112890", 
            "org_study_id": "201076"
        }, 
        "intervention": {
            "arm_group_label": "Study Group", 
            "description": "Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.", 
            "intervention_name": "Data collection", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mexico", 
            "Adolescents", 
            "Hepatitis", 
            "Seroprevalence", 
            "Pertussis", 
            "Young adults"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "number_of_groups": "1", 
        "official_title": "Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HAV", 
                "safety_issue": "No", 
                "time_frame": "During the study (approximately 12 months)"
            }, 
            {
                "measure": "Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HBV (Hepatitis B core antibody [anti-HBc], Hepatitis B surface antigen [HBsAg]) and Hepatitis B surface antibody (anti-HBs)", 
                "safety_issue": "No", 
                "time_frame": "During the study (approximately 12 months)"
            }, 
            {
                "measure": "Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for Pertussis antibodies", 
                "safety_issue": "No", 
                "time_frame": "During the study (approximately 12 months)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112890"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Assesment of the difference in HAV, HBV and B. pertussis seropositivity rates among - Socioeconomic strata, - Regions, - Age groups, - Genders, - Risk groups, - Vaccination status for B. pertussis (if available)", 
            "safety_issue": "No", 
            "time_frame": "During the study (approximately 12 months)"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}